Banyan Capital Management Inc. Has $9.24 Million Position in Henry Schein, Inc. $HSIC

Banyan Capital Management Inc. lifted its stake in shares of Henry Schein, Inc. (NASDAQ:HSIC) by 8.8% during the 3rd quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The fund owned 139,141 shares of the company’s stock after purchasing an additional 11,229 shares during the quarter. Henry Schein accounts for about 4.2% of Banyan Capital Management Inc.’s portfolio, making the stock its 12th largest position. Banyan Capital Management Inc.’s holdings in Henry Schein were worth $9,235,000 as of its most recent filing with the Securities and Exchange Commission.

Several other institutional investors and hedge funds have also added to or reduced their stakes in the stock. Truist Financial Corp boosted its position in Henry Schein by 3.3% in the third quarter. Truist Financial Corp now owns 5,540 shares of the company’s stock valued at $368,000 after buying an additional 175 shares in the last quarter. First Citizens Bank & Trust Co. increased its holdings in shares of Henry Schein by 2.4% during the third quarter. First Citizens Bank & Trust Co. now owns 98,804 shares of the company’s stock worth $6,558,000 after buying an additional 2,329 shares in the last quarter. Blackhawk Capital Partners LLC lifted its stake in shares of Henry Schein by 7.3% in the 3rd quarter. Blackhawk Capital Partners LLC now owns 3,867 shares of the company’s stock valued at $257,000 after acquiring an additional 264 shares during the last quarter. Mitsubishi UFJ Trust & Banking Corp boosted its holdings in shares of Henry Schein by 105.2% during the 3rd quarter. Mitsubishi UFJ Trust & Banking Corp now owns 6,007 shares of the company’s stock valued at $399,000 after acquiring an additional 3,079 shares in the last quarter. Finally, UniSuper Management Pty Ltd boosted its holdings in shares of Henry Schein by 15.5% during the 3rd quarter. UniSuper Management Pty Ltd now owns 27,429 shares of the company’s stock valued at $1,820,000 after acquiring an additional 3,672 shares in the last quarter. Institutional investors own 96.62% of the company’s stock.

Analyst Ratings Changes

A number of brokerages have issued reports on HSIC. Morgan Stanley upped their target price on Henry Schein from $55.00 to $58.00 and gave the stock an “underweight” rating in a report on Wednesday, November 5th. JPMorgan Chase & Co. boosted their price target on Henry Schein from $76.00 to $78.00 and gave the stock an “overweight” rating in a report on Wednesday, November 5th. Mizuho set a $81.00 price objective on shares of Henry Schein and gave the company a “neutral” rating in a report on Tuesday, January 20th. Barclays assumed coverage on shares of Henry Schein in a research report on Monday, December 8th. They set an “overweight” rating and a $86.00 target price on the stock. Finally, Barrington Research set a $79.00 target price on shares of Henry Schein and gave the stock an “outperform” rating in a report on Wednesday, November 5th. Five analysts have rated the stock with a Buy rating, six have issued a Hold rating and one has assigned a Sell rating to the company. According to data from MarketBeat.com, the company presently has an average rating of “Hold” and a consensus target price of $76.42.

Henry Schein Price Performance

Henry Schein stock opened at $74.34 on Friday. The stock’s 50 day moving average is $76.25 and its 200 day moving average is $70.75. Henry Schein, Inc. has a one year low of $60.56 and a one year high of $82.49. The firm has a market cap of $8.75 billion, a P/E ratio of 23.53, a P/E/G ratio of 2.24 and a beta of 0.88. The company has a debt-to-equity ratio of 0.54, a current ratio of 1.40 and a quick ratio of 0.79.

Henry Schein (NASDAQ:HSIC) last released its earnings results on Tuesday, November 4th. The company reported $1.38 earnings per share for the quarter, beating analysts’ consensus estimates of $1.27 by $0.11. The business had revenue of $3.34 billion during the quarter, compared to the consensus estimate of $3.28 billion. Henry Schein had a net margin of 3.02% and a return on equity of 14.76%. Henry Schein has set its FY 2025 guidance at 4.880-4.960 EPS. As a group, research analysts expect that Henry Schein, Inc. will post 4.74 EPS for the current year.

About Henry Schein

Henry Schein, Inc is a leading global distributor of healthcare products and services, primarily serving office-based dental, medical and animal health practitioners. The company operates through three principal segments—Schein Dental, Schein Medical and Animal Health—each offering a comprehensive portfolio of consumable products, equipment, instruments and related value-added services. With a focus on improving practice efficiency and patient care, Henry Schein provides everything from dental restorative materials and orthodontic appliances to vaccines, pharmaceuticals and diagnostic devices for physicians, as well as pet health products and veterinary equipment for animal health professionals.

In addition to its broad product offering, Henry Schein delivers a suite of technology and service solutions aimed at streamlining workflows and enhancing clinical outcomes.